Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB)

Analyst Roy from JonesTrading noted that his bullish sentiment is based connected the upcoming information from a survey of Safusidenib. It is an IDH1 inhibitor for patients who person undergone surgery. Roy expects information from the survey by the extremity of the year. The expert noted that helium has accrued the occurrence probability of Safusidenib from 30% to 50%. He besides expects accelerated support with motorboat present anticipated successful 2029 alternatively than 2030.

That said, connected January 13, H.C. Wainwright lowered the terms people connected the banal from $18 to $17, portion maintaining a Buy standing connected the stock. The steadfast highlighted that the reduced terms people is owed to IBTROZI’s fiscal Q4 2025 income of $15.7 million, which volition beryllium beneath the firm’s expectations of $16.4 million. However, the income fig was inactive successful enactment with the wide statement of $15.5 million.  As a result, the steadfast lowered its 2026 income people to $163.2 cardinal from $169.6 million.

Nuvation Bio Inc. (NYSE:NUVB) is simply a biopharmaceutical institution focused connected the improvement of caller oncology therapies.

While we admit the imaginable of NUVB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.